View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	DISCOVERY LABORATORIES INC /DE/
Entity Central Index Key	0000946486
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		80,749,022
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 21,177	$ 26,892
Inventory	117	195
Prepaid expenses and other current assets	418	719
Total Current Assets	21,712	27,806
Property and equipment, net	1,417	1,737
Restricted cash	400	400
Other assets	102	0
Total Assets	23,631	29,943
Current Liabilities:
Accounts payable	1,489	1,166
Accrued expenses	5,071	4,159
Common stock warrant liability	4,678	6,305
Equipment loans and capitalized leases, current portion	72	69
Total Current Liabilities	11,310	11,699
Long-term debt, net of discount of $3,674 at September 30, 2013 and $0 at December 31, 2012	6,326	0
Equipment loans and capitalized leases, non-current portion	89	148
Other liabilities	431	443
Total Liabilities	18,156	12,290
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized at September 30, 2013, 100,000,000 shares authorized at December 31, 2012; 54,946,327 and 43,673,636 shares issued, 54,925,435 and 43,652,744 shares outstanding at September 30, 2013 and December 31, 2012, respectively	55	44
Additional paid-in capital	476,695	455,398
Accumulated deficit	(468,221)	(434,735)
Treasury stock (at cost); 20,892 shares	(3,054)	(3,054)
Total Stockholders' Equity	5,475	17,653
Total Liabilities & Stockholders' Equity	$ 23,631	$ 29,943

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
LIABILITIES & STOCKHOLDERS' EQUITY
Unamortized discount	$ 3,674	$ 0
Stockholders' Equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	100,000,000
Common stock, shares issued (in shares)	54,946,327	43,673,636
Common stock, shares outstanding (in shares)	54,925,435	43,652,744
Treasury stock (at cost) (in shares)	20,892	20,892

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Operations (Unaudited) [Abstract]
Grant revenue	$ 60	$ 0	$ 315	$ 0
Expenses:
Research and development	6,574	5,743	21,909	15,482
Selling, general and administrative	4,299	4,255	12,648	9,912
Total expenses	10,873	9,998	34,557	25,394
Operating loss	(10,813)	(9,998)	(34,242)	(25,394)
Change in fair value of common stock warrant liability	(1,059)	(3,309)	1,627	(5,063)
Interest income	1	1	2	5
Interest expense	(353)	(4)	(873)	(12)
Other expense	0	(36)	0	(36)
Net loss	$ (12,224)	$ (13,346)	$ (33,486)	$ (30,500)
Net loss per common share
Basic (in dollars per share)	$ (0.22)	$ (0.31)	$ (0.68)	$ (0.80)
Diluted (in dollars per share)	$ (0.22)	$ (0.31)	$ (0.69)	$ (0.80)
Weighted average number of common shares outstanding
Basic (in shares)	54,792	43,444	49,235	38,061
Diluted (in shares)	54,792	43,444	50,377	38,061

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flow from operating activities:
Net loss	$ (33,486)	$ (30,500)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	537	855
Stock-based compensation and 401(k) match	2,367	1,805
Fair value adjustment of common stock warrants	(1,627)	5,063
Loss on sale or disposal of equipment	0	36
Amortization of discount on long-term debt	302	0
Changes in:
Inventory	78	(128)
Prepaid expenses and other current assets	301	(723)
Accounts payable	323	(903)
Accrued expenses	912	693
Other assets	(115)	0
Other liabilities	(12)	(19)
Net cash used in operating activities	(30,420)	(23,821)
Cash flows from investing activities:
Purchase of property and equipment	(204)	(593)
Net cash used in investing activities	(204)	(593)
Cash flows from financing activities:
Proceeds from issuance of securities, net of expenses	15,114	43,605
Proceeds from issuance of long-term debt, net of expenses	9,850	0
Proceeds from exercise of common stock warrants and options	1	6,741
Repayment of equipment loans and capital lease obligations	(56)	(57)
Net cash provided by financing activities	24,909	50,289
Net (decrease) / increase in cash and cash equivalents	(5,715)	25,875
Cash and cash equivalents - beginning of period	26,892	10,189
Cash and cash equivalents - end of period	21,177	36,064
Supplementary disclosure of cash flows information:
Interest paid	$ 559	$ 10

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2013
Organization and Business [Abstract]
Organization and Business	Note 1 – Organization and Business Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a specialty biotechnology company focused on creating life-saving products for critical care patients with respiratory disease and improving the standard of care in pulmonary medicine. Our proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. We are developing our KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. We are also developing novel drug delivery technologies potentially to enable the efficient delivery of our aerosolized KL4 surfactant, and potentially other aerosolized drugs and inhaled therapies. We believe that our proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. Our near-term focus is to develop our KL4 surfactant and drug delivery technologies to improve the management of respiratory distress syndrome (RDS) in premature infants. RDS is a serious respiratory condition caused by insufficient surfactant production in underdeveloped lungs of premature infants, and the most prevalent respiratory disease in the neonatal intensive care unit (NICU). RDS can result in long-term respiratory problems, developmental delay and death. Currently, premature infants with RDS are treated with surfactants that can only be administered by endotracheal intubation supported with mechanical ventilation, both invasive procedures that may result in serious respiratory conditions and complications. To avoid such adverse results, neonatologists generally provide surfactants as initial therapy only to premature infants with severe RDS where the potential benefits of surfactant therapy outweigh the risks associated with endotracheal intubation and mechanical ventilation. For infants with less severe RDS, neonatologists first attempt to provide respiratory support using a less invasive means, such as nasal continuous positive airway pressure (nCPAP). Unfortunately, a significant number of these infants do not respond adequately to nCPAP, an outcome referred to as nCPAP failure, and require subsequent surfactant administration via intubation and mechanical ventilation. Since it is not possible to ascertain which patients will experience nCPAP failure, neonatologists treating less severe RDS are faced with a dilemma, because the outcome for those infants who experience nCPAP failure and receive delayed surfactant therapy may not be as favorable as the outcome for those infants who receive surfactant therapy as initial therapy. With mortality and morbidity rates that have not meaningfully improved over the last decade, we believe that the RDS market is presently underserved. We also believe that our RDS programs, including SURFAXIN^® and, if approved, AEROSURF^®, have the potential to greatly improve the management of RDS and, over time, become a new standard of care for premature infants with RDS. Moreover, we believe that the neonatal community is increasingly recognizing the potential benefits of (i) a synthetic, peptide-containing surfactant, and more importantly, (ii) a less-invasive method of delivering aerosolized surfactant to treat premature infants at risk of suffering from respiratory disorders. In 2012, the U.S. Food and Drug Administration (FDA) approved our first KL4 surfactant drug product, SURFAXIN (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants currently used in the U.S. On October 4, 2013, we announced that the FDA agreed to updated product specifications that we previously submitted for SURFAXIN. On November 8, 2013, we announced that we have initiated the commercial introduction of SURFAXIN. Our commercial and medical affairs organizations currently are advancing initiatives to communicate that SURFAXIN is available and to secure formulary acceptance from our target hospitals. We are also preparing to support hospitals that order SURFAXIN with in-service training, medical information and other activities intended to promote and enable a deliberate and orderly introduction of SURFAXIN to the neonatal community. AEROSURF is an investigational combination drug-device product that combines our KL4 surfactant with our proprietary capillary aerosol generator (CAG). We are developing AEROSURF to deliver our KL4 surfactant in aerosolized form to premature infants with RDS. AEROSURF potentially will provide neonatologists with the ability to avoid the invasive procedures currently required to administer surfactant therapy and deliver our KL4 surfactant in aerosolized form to premature infants supported with nCPAP. For this reason, we believe that AEROSURF, if approved, may enable the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated. On October 17, 2013, we announced that we have submitted an Investigational New Drug (IND) Application to the FDA for our initial AEROSURF phase 2 clinical trial. The FDA has completed its review and cleared IND and we expect to initiate our phase 2 clinical program in the fourth quarter of 2013. We are developing a lyophilized (freeze-dried) dosage form of our KL4 surfactant, which is stored as a powder and resuspended to liquid form prior to use, and is being developed with the objective of improving ease of use for healthcare practitioners, as well as potentially prolonging shelf life and eliminating the need for cold-chain storage. We are planning initially to use lyophilized KL4 surfactant in our AEROSURF development program. We are also assessing a potential development plan intended to gain regulatory approval for SURFAXIN LS™, a lyophilized dosage form of SURFAXIN, in the U.S. and potentially in other markets. With the assistance of Battelle Memorial Institute (Battelle), we have completed development of a clinic-ready CAG device, which has passed a rigorous design verification testing program, and have manufactured a sufficient number of clinic-ready CAGs to support the initial phase of our AEROSURF phase 2 clinical program. We plan to continue development of our CAG and expect to manufacture additional devices to support completion of our phase 2 clinical program and potentially our phase 3 clinical program. The CAG has been designed to produce aerosolized KL4 surfactant in volumes up to 10 times the output produced by currently available aerosol devices. AFECTAIR^® aerosol-conducting airway connector is our novel disposable device intended to simplify the delivery of our aerosolized KL4 surfactant, and other aerosolized medications and inhaled therapies, to infants in NICUs and pediatric intensive care units (PICUs) who require ventilatory support by introducing the aerosolized medication directly at the patient interface and minimizing the number of connections in the ventilator circuit. To gain information and assess the use of this device in different clinical settings, we are continuing a national user experience program at a number of institutions, including leading neonatal thought centers, across the U.S. We have established our own specialty commercial and medical affairs organizations to focus on neonatal/pediatric respiratory critical care in hospitals across the U.S. These organizations are primarily responsible for the commercial introduction of SURFAXIN and the AFECTAIR device. In the future, we expect that these teams will be able to leverage the experience and relationships gained from the introduction of SURFAXIN to support the potential introductions of our own future pipeline products, beginning with, if approved, AEROSURF and potentially SURFAXIN LS. In addition, we will consider opportunities to leverage our experience and relationships to market and support other synergistic products that could be of benefit in the NICU/PICU. Our objectives for 2013 include initiating the commercial introduction of SURFAXIN and advancing the AEROSURF phase 2 clinical program. In the future, we expect that we will be able to apply the knowledge and experience gained from these activities to develop a pipeline of innovative products based on our technologies and intended to address other critical care respiratory conditions in the NICU, PICU and intensive care units (ICUs). An important priority for us is to secure strategic and financial resources to advance our KL4 surfactant and aerosol device development programs and the commercial introduction of our approved RDS products in markets outside the U.S. See, Note 2, “Liquidity Risks and Management’s Plans.” While we currently intend to retain all rights and commercialize our approved products in the U.S., we are focused on identifying potential strategic alliances to assist us with our development programs in markets outside the U.S. We seek strategic partners that have broad experience in the designated markets, including regulatory and product development expertise as well as an ability to commercialize our products. In addition to development and commercial support, such alliances typically also would provide us with financial resources to support our activities, potentially in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses. We are focused on securing a significant strategic alliance predominantly to support our activities in the European Union (EU). To date, the primary focus of our discussions has been on AEROSURF. In the future, we may also seek strategic alliances and/or collaboration arrangements to support the potential commercial introduction of SURFAXIN and, if approved, SURFAXIN LS, in countries where regulatory approval is facilitated by the information contained in our SURFAXIN new drug application (NDA) approved by the FDA. There can be no assurance that we will be successful in securing the necessary capital, or concluding any strategic alliance, collaboration arrangement or other similar transaction. See, Note 2, “Liquidity Risks and Management’s Plans.”

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Liquidity Risks and Management's Plans	9 Months Ended
Liquidity Risks and Management's Plans	Sep. 30, 2013
Liquidity Risks and Management's Plans [Abstract]
Liquidity Risks and Management's Plans	Note 2 – Liquidity Risks and Management’s Plans We have incurred substantial losses since inception, due to investments in research and development, manufacturing and potential commercialization activities, and we expect to continue to incur substantial losses over the next several years. Historically, we have funded our business operations through various sources, including public and private securities offerings, debt facilities, strategic alliances, the use of Committed Equity Financing Facilities (CEFFs) and at-the-market equity programs, and capital equipment financings. As of September 30, 2013, we had cash and cash equivalents of $21.2 million, approximately $6.6 million of accounts payable and accrued expenses, and $10 million of long-term debt under our Deerfield Facility with Deerfield Management Company, L.P. (Deerfield). On October 15, 2013, we completed an offering under our At-the-Market Program (ATM Program) (see, Note 4, “Stockholders’ Equity – Common Stock Offerings – At-the-Market Program”) with Stifel, Nicolaus & Company, Incorporated (Stifel) and issued 713,920 shares of our common stock resulting in net proceeds to us (after deducting commissions due to Stifel) of approximately $1.9 million. Through our ATM Program, subject to market conditions, we have the ability to sell up to approximately $23 million of common stock at such times and in such amounts that we deem appropriate. However, use of the ATM Program is subject to market and other conditions and the ATM Program can be cancelled at any time by either party. There can be no assurance that the ATM Program will be available when needed, if at all. On November 5, 2013, we completed a public offering of 25 million shares of common stock, at a price of $2.00 per share resulting in gross proceeds of $50.0 million ($46.8 million net after commissions, discounts and expenses). In addition, we also granted the underwriters a 30-day option to purchase up to an additional 3.75 million shares of common stock (over-allotment) at an offering price of $2.00 per share. On November 8, 2013, we received notification that the underwriters have exercised the full over-allotment and will purchase an additional 3.75 million shares. This transaction is expected to close on or about November 14, 2013 and result in additional net proceeds to us of approximately $7.1 million. We also have met the conditions for, and expect in early December to receive, an additional advance of $20 million under the Deerfield Facility, which became due upon the first commercial sale of SURFAXIN drug product. See, Note 6, “Long-Term Debt – Loan Facility with Deerfield.” Before any additional financings, including under our ATM Program and taking into account the additional approximately $7.1 million expected from the underwriters’ exercise of the over-allotment in our November public offering and the expected $20 million advance under the Deerfield Facility, we anticipate that we will have sufficient cash available to support our operations and debt service obligations through 2015. Our future capital requirements depend upon many factors, primarily the success of our efforts to (i) execute the commercial introduction of SURFAXIN and AFECTAIR in the U.S., as planned; (ii) advance the AEROSURF development program to completion of the phase 2 clinical program in mid-2015; and (iii) secure one or more strategic alliances or other collaboration arrangements to support the development and, if approved, the commercial introduction of SURFAXIN, AEROSURF, AFECTAIR and potentially SURFAXIN LS, in markets outside the U.S. We believe that, if we are successful with the commercial introduction of SURFAXIN and if we are able to complete the AEROSURF phase 2 clinical program on a timely basis and obtain encouraging results, our ability to enter into a significant strategic alliance will be enhanced. There can be no assurance, however, that our efforts will be successful, or that we will be able to obtain additional capital to support our activities when needed on acceptable terms, if at all. Even if we succeed with the commercial introduction of SURFAXIN and the AFECTAIR device as planned, given the time required to secure formulary acceptance of SURFAXIN at our target hospitals, we expect our revenues from SURFAXIN and AFECTAIR to be modest in the first 12-18 months and then increase over time as our products gain hospital acceptance. As a result, our cash outflows for operations, debt service and development programs are expected to outpace the rate at which we may generate revenues for several years. To execute our business strategy and fund our operations over the long term, we will require significant additional infusions of capital until such time as the net revenues from SURFAXIN, AFECTAIR and, if approved, AEROSURF, from potential strategic alliances and from other sources are sufficient to offset our cash flow requirements. To secure the necessary capital, we would prefer to enter into strategic alliances or collaboration agreements with partners that could provide development and commercial expertise as well as financial resources (potentially in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses) and introduce our approved products in various markets outside the U.S. We also plan to consider other public and private equity offerings, including under our ATM Program, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions. As of September 30, 2013, we had outstanding warrants to purchase approximately 10.3 million shares of our common stock at various prices, exercisable on different dates through 2019. Of these warrants, approximately 2.3 million warrants were issued to Deerfield in connection with the first advance under the Deerfield Facility. Upon receipt of the final $20 million advance under the Deerfield Facility, which is anticipated on or about December 3, 2013, we will issue warrants to purchase an additional 4.66 million shares of our common stock at an exercise price of $2.81 per share (we refer to these warrants and the warrants previously issued to Deerfield as the Deerfield Warrants). The Deerfield Warrants may be exercised for cash or on a cashless basis. In lieu of paying cash upon exercise, the holders also may elect to reduce the principal amount of the Deerfield loan in an amount sufficient to satisfy the exercise price of the Deerfield Warrants. In addition to the Deerfield Warrants, we have outstanding warrants to purchase approximately 4.9 million shares of common stock that were issued in February 2011, are exercisable for five-years, and contain anti-dilution provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. These warrants were originally issued with an exercise price of $3.20 per share and thereafter adjusted downward, first to $2.80 per share following a public offering in March 2012 and then to $1.50 per share following a public offering in May 2013. Although we believe that, in the future, we will secure additional capital from the exercise of at least a portion of our outstanding warrants, there can be no assurance that the market price of our common stock will equal or exceed price levels that make exercise of outstanding warrants likely, or, even if the price levels are sufficient, that holders of our warrants will choose to exercise any or all of their warrants prior to the warrant expiration date. Moreover, if our outstanding warrants are exercised, such exercises likely will be at a discount to the then-market value of our common stock and have a dilutive effect on the value of our shares of common stock at the time of exercise. As of September 30, 2013, 150 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation, and approximately 71.7 million shares of common stock were available for issuance and not otherwise reserved. As of November 8, 2013, following the financings under our ATM Program, our public offering, and establishment of additional reserves for the shares expected to be issued in connection with the underwriters’ exercise of the over-allotment in our November public offering and with respect to the warrants expected to be issued to Deerfield upon receipt of the $20 million advance in early December, approximately 42 million shares of common stock were available for issuance and not otherwise reserved. Although we currently believe that we will be able to execute our business plan and accomplish our objectives, there can be no assurance that we will be successful. There can be no assurance that we will be successful in securing the needed capital, through strategic alliances, collaboration arrangements, financings, debt arrangements and other transactions. Failure to secure the necessary additional capital would have a material adverse effect on our business, financial condition and results of operations.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form 10‑Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. There have been no changes to our critical accounting policies since December 31, 2012. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 that we filed with the Securities and Exchange Commission (SEC) on March 15, 2013 (2012 Form 10-K). Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Inventory

Inventories are determined at the lower of cost or market value with cost determined under the specific identification method. We assess the potential capitalization of inventory and the timing of when the related costs are expected to be recoverable through the commercialization of our products. Costs incurred prior to FDA approval of SURFAXIN drug product and registration of our initial AFECTAIR device have been recorded in our statement of operations as research and development expense. Due to a delay in commercial availability of SURFAXIN drug product, previously capitalized raw material costs of $195,072 were charged to research and development expense in the first quarter of 2013, as these raw materials were no longer expected to be used for commercial production.

Inventory as of September 30, 2013 consists of AFECTAIR devices available for commercial sale. Inventory costs for our AFECTAIR device consist primarily of third-party manufacturing fees, freight, and indirect personnel overhead costs.

Research and development expense

We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred. For the nine months ended September 30, 2012, research and development expense includes a $0.5 million charge related to a milestone payment that became payable to Johnson & Johnson (J&J) upon FDA approval of SURFAXIN, in accordance with terms of our license agreement with J&J.

Net loss per common share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period.

In accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings per Share,” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants. For the nine months ended September 30, 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive. For the three months ended September 30, 2013 and for the three and nine months ended September 30, 2012, the effect of the adjustments for all warrants classified as derivative liabilities was non-dilutive.

The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Numerator:
Net loss as reported	$	(12,224	)	$	(13,346	)	$	(33,486	)	$	(30,500	)
Less: income from change in fair value of warrant liability		–			–			(1,525	)		–
Numerator for diluted net loss per common share	$	(12,224	)	$	(13,346	)	$	(35,011	)	$	(30,500	)

Denominator:
Basic weighted average common shares outstanding		54,792			43,444			49,235			38,061
Dilutive common shares from assumed warrant exercises		–			–			1,142			–
Diluted weighted average common shares outstanding		54,792			43,444			50,377			38,061

As of September 30, 2013 and 2012, 10.7 million and 12.0 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.

Recent accounting pronouncements

There were no new accounting pronouncements issued during the nine months ended September 30, 2013 that are expected to have a material impact on the Company’s financial position, operating results, cash flows or disclosures.

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2013

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 5 – Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets and liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The table below categorizes assets and liabilities measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012:

	Fair Value		Fair value measurement using
	September 30, 2013		Level 1		Level 2		Level 3

Assets:
Money Market	$	19,877	$	19,877	$	–	$	–
Certificate of Deposit		400		400		–		–
Total Assets	$	20,277	$	20,277	$	–	$	–

Liabilities:
Common stock warrant liability	$	4,678	$	–	$	–	$	4,678

	Fair Value		Fair value measurement using
	December 31, 2012		Level 1		Level 2		Level 3

Assets:
Money Market	$	23,377	$	23,377	$	–	$	–
Certificate of Deposit		400		400		–		–
Total Assets	$	23,777	$	23,777	$	–	$	–

Liabilities:
Common stock warrant liability	$	6,305	$	–	$	–	$	6,305

The tables below summarizes the activity of Level 3 inputs measured on a recurring basis for the nine months ended September 30, 2013 and 2012:

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2012	$	6,305
Change in fair value of common stock warrant liability		(1,627	)
Balance at September 30, 2013	$	4,678

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2011	$	6,996
Exercise of warrants		(136	)
Change in fair value of common stock warrant liability		5,063
Balance at September 30, 2012	$	11,923

The significant unobservable inputs used in the fair value measurement of common stock warrants are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, the fair value measurement of certain five-year warrants issued in February 2011 also takes into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, would result in significantly higher or lower fair value measurements.

Significant Unobservable Input Assumptions of Level 3 Valuations	September 30, 2013			December 31, 2012

Historical Volatility		55% - 61	%		56% -80	%
Expected Term (in years)		0.6 – 2.4			1.4 – 3.2
Risk-free interest rate		0.05% - 0.45	%		0.16% - 0.36	%

Fair Value of Long-Term Debt

As of September 30, 2013, the carrying value of our long-term debt, net of discounts, approximates fair value. We had no long-term debt as of December 31, 2012. We estimate the fair value of the Deerfield Facility using a discounted cash flow analysis. This analysis utilizes certain Level 3 unobservable inputs, including the effective interest rate and current cost of capital. Considerable judgment is required to interpret market data and to develop estimates of fair value. The estimates presented are not necessarily indicative of amounts we could realize in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Long-term Debt

9 Months Ended

Sep. 30, 2013

Long-term Debt [Abstract]

Long-term Debt

Note 6 – Long-term Debt

Loan Facility with Deerfield

On February 13, 2013, we entered into a secured loan facility (Deerfield Facility) with affiliates of Deerfield Management Company, L.P. (Deerfield) for up to $30 million in secured financing in 2013. Deerfield advanced to us $10 million upon execution of the agreement and agreed to advance an additional $20 million, subject to certain conditions, on or about the date of the first commercial sale of SURFAXIN drug product (Milestone Date), if the Milestone Date occurs on or before December 31, 2013. On November 8, 2013, we notified Deerfield that the first commercial sale of SURFAXIN has occurred, and anticipate receipt of the $20 million advance on or about December 3, 2013.

The loan may be prepaid in whole or in part without penalty at any time. In addition, the principal amount of the loan may be reduced to the extent that holders of the notes elect to apply all or a portion of the principal amount outstanding under the loan to satisfy the exercise price of all or a portion of the Deerfield Warrants upon exercise. The principal amount of the loan is payable in equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Facility agreement, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) our “Net Sales” (defined below) for the immediately preceding 12-month period are at least $20 million, or (ii) our “Equity Value” (defined below) is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) our “Net Sales” for the immediately preceding 12 month period are at least $30 million, or (ii) our “Equity Value” is at least $250 million. For the purposes of the foregoing deferrals of principal, “Net Sales” means, without duplication, the gross amount invoiced by us or on our behalf, any of our subsidiaries or any direct or indirect assignee or licensee for products, sold globally in bona fide, arm’s length transactions, less customary deductions determined without duplication in accordance with generally accepted accounting principles; and “Equity Value” means, with respect to each measurement date, the product of (x) the number of issued and outstanding shares of our common stock on such measurement date multiplied by (y) the per share closing price of our common stock on such measurement date. Accordingly, if the milestones are achieved in each year, payment of the principal amount could be deferred until the sixth anniversary date of the loan on February 13, 2019.

Any amounts received and outstanding under the Deerfield Facility will accrue interest at a rate of 8.75%, payable quarterly in cash. The Deerfield Facility agreement contains customary terms and conditions but does not require us to meet minimum financial and revenue performance covenants. In connection with each advance, Deerfield has received and, upon advance of the additional $20 million, will receive, a transaction fee equal to 1.5% of the amount disbursed. The facility agreement also contains various representations and warranties and affirmative and negative covenants customary for financings of this type, including restrictions on our ability to incur additional indebtedness and grant additional liens on our assets. In addition, all amounts outstanding under the Deerfield Facility may become immediately due and payable upon (i) an “Event of Default,” as defined in the Deerfield Facility agreement, in which case Deerfield would have the right to require us to repay the outstanding principal amount of the loan, plus any accrued and unpaid interest thereon, or (ii) the occurrence of certain events as defined in the facility agreement, including, among other things, the consummation of a change of control transaction or the sale of more than 50% of our assets (a Major Transaction).

In connection with the execution of the Deerfield Facility and receipt of the initial disbursement of $10 million, we issued to Deerfield warrants to purchase approximately 2.3 million shares of our common stock at an exercise price of $2.81. Upon disbursement of the additional $20 million loan under the facility agreement, we will issue additional warrants to Deerfield to purchase an additional 4.66 million shares of our common stock at an exercise price of $2.81 per share of common stock. The number of shares of common stock into which the Deerfield Warrants are exercisable and the exercise price of any Deerfield Warrant will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock.

The Deerfield Warrants will expire on the sixth anniversary of the facility agreement and contain certain limitations that generally prevent the holder from acquiring shares upon exercise of a Deerfield Warrant that would result in the number of shares beneficially owned by it to exceed 9.985% of the total number of shares of common stock then issued and outstanding. The holder of a Deerfield Warrant may exercise all or a portion of such Deerfield Warrant either for cash or on a cashless basis. In connection with a Major Transaction, as defined in the Deerfield Warrants, to the extent of consideration payable to stockholders in cash in connection with such Major Transaction, the holder may have the option to redeem the Deerfield Warrant or that portion of the Deerfield Warrant for cash in an amount equal to the Black-Scholes value (as defined in the Deerfield Warrant) of the Deerfield Warrant or that portion of the Deerfield Warrant redeemed. In addition, in connection with a Major Transaction, to the extent of any consideration payable to stockholders in securities, or in the event of an Event of Default, the holder may have the option to exercise the Deerfield Warrant and receive therefor that number of shares of Common Stock that equals the Black-Scholes value of the Deerfield Warrant or that portion of the Deerfield Warrant exercised. Prior to the holder exercising the Deerfield Warrant for shares in such transactions, the Company may elect to terminate the Deerfield Warrant or that portion of the Deerfield Warrant and pay the holder cash in an amount equal to the Black-Scholes value of the Deerfield Warrant.

We have recorded the loan as long-term debt at its face value of $10.0 million less debt discounts and issuance costs consisting of (i) $3.8 million fair value of the Deerfield Warrants issued upon the advance of the $10 million initial disbursement, and (ii) a $150,000 transaction fee. The discount is being accreted to the $10 million loan over its term using the effective interest method. The Deerfield Warrants are derivatives that qualify for an exemption from liability accounting as provided for in ASC Topic 815 “Derivatives and Hedging – Contracts in Entity’s Own Equity” (ASC 815) and have been classified as equity.

The fair value of the Deerfield Warrants at issuance was calculated using the Black-Scholes option-pricing model. The significant Level 3 unobservable inputs used in valuing the Deerfield Warrants are the historical volatility of our common stock market price, expected term of the warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, would have resulted in a significantly higher or lower fair value measurement.

Significant Unobservable Input Assumptions of Level 3 Valuations

Historical Volatility	101	%
Expected Term (in years)	6.0
Risk-free interest rate	1.175	%

Long-term debt as of September 30, 2013 consists solely of amounts due under the Deerfield Facility as follows:

Note Payable	$	10,000
Unamortized discount		(3,674	)
Long-term debt, net of discount	$	6,326

The following amounts comprise the Deerfield Facility interest expense for the periods presented:

(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012

Cash interest expense	$	221	$	–	$	551	$	–
Non-cash amortization of debt discounts		125		–		302		–
Amortization of debt costs		5		–		13		–
Total Deerfield Facility interest expenses	$	351	$	–	$	866	$	–

Cash interest expense represents interest of 8.75% on the outstanding principal amount for the period, paid in cash on a quarterly basis. Non-cash amortization of debt discount represents the amortization of transaction fees and the fair value of the warrants issued in connection with the Deerfield Facility. The amortization of debt costs represents legal costs incurred in connection with the Deerfield Facility.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Inventory

Research and development expense

Net loss per common share

The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Numerator:
Net loss as reported	$	(12,224	)	$	(13,346	)	$	(33,486	)	$	(30,500	)
Less: income from change in fair value of warrant liability		–			–			(1,525	)		–
Numerator for diluted net loss per common share	$	(12,224	)	$	(13,346	)	$	(35,011	)	$	(30,500	)

Denominator:
Basic weighted average common shares outstanding		54,792			43,444			49,235			38,061
Dilutive common shares from assumed warrant exercises		–			–			1,142			–
Diluted weighted average common shares outstanding		54,792			43,444			50,377			38,061

Recent accounting pronouncements

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4492-108314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4556-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 81-1
-Paragraph 69-75
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Paragraph 3, 5-10, 15, 16, 17
-Chapter 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 206
-Paragraph b
-Subparagraph i, ii
-Chapter 2

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 9
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

+ Details

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References + Details

Liquidity Risks and Management's Plans (Details) $ in Thousands				1 Months Ended		9 Months Ended
	Nov. 05, 2013 USD ($) $ / shares shares	May 31, 2013 shares	May 15, 2013 $ / shares shares	Nov. 30, 2013 USD ($) shares	Oct. 31, 2013 USD ($) shares	Sep. 30, 2013 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Nov. 08, 2013 shares	Dec. 31, 2012 USD ($) shares	Mar. 31, 2012 $ / shares	Dec. 31, 2011 USD ($)	Feb. 28, 2011 $ / shares
Liquidity Risks and Management's Plans [Abstract]
Cash and cash equivalents						$ 21,177	$ 36,064		$ 26,892		$ 10,189
Accounts payable and accrued expenses						6,600
Stockholders' Equity [Line Items]
Net proceeds from issuance of common stock						15,114	$ 43,605
Class of Warrant or Right [Line Items]
Second disbursement under loan facility						$ 20,000
Number of warrant shares outstanding (in shares) \| shares						10,300,000
Common stock, shares authorized (in shares) \| shares						150,000,000			100,000,000
Common stock available for future issuance (in shares) \| shares						71,700,000
First disbursement under loan facility						$ 10,000
Exercise price of warrants (in dollars per share) \| $ / shares						2.81
Deerfield Management Company [Member]
Class of Warrant or Right [Line Items]
Second disbursement under loan facility						$ 20,000
Number of warrant shares outstanding (in shares) \| shares						2,300,000
Proceeds from secured loan upon execution of the agreement						$ 10,000
Exercise price of warrants (in dollars per share) \| $ / shares						2.81
ATM Program [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock issued in public offering (in shares) \| shares					713,920
Net proceeds from issuance of common stock					$ 1,900
Maximum value of potential common stock available for issue					$ 23,000	$ 25,000
Registered Public Offerings [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock issued in public offering (in shares) \| shares	25,000,000		9,500,000
Per share price of common stock issuance (in dollars per share) \| $ / shares	$ 2.00		$ 1.50
Gross proceeds from issuance of common stock	$ 50,000
Net proceeds from issuance of common stock	$ 46,800
Over Allotment Exercise Period	30 days		30 days
Number of additional shares of common stock that may be issued upon exercise of over allotment (in shares) \| shares	3,750,000		1,425,000
Number of shares of common stock issued upon exercise of overallotment (in shares) \| shares		1,347,000		3,750,000
Net proceeds from over allotment exercised				$ 7,100
Class of Warrant or Right [Line Items]
Common stock available for future issuance (in shares) \| shares								42,000,000
Five Year Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrant shares outstanding (in shares) \| shares						4,900,000
Exercise price of warrants (in dollars per share) \| $ / shares						1.50				2.80		3.20
Deerfield Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrant shares issuable (in shares) \| shares						4,660,000
Exercise price of warrants (in dollars per share) \| $ / shares						2.81

Summary of Significant Accounting Policies (Details) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Inventory [Abstract]
Capitalized raw material now charged to research and development account					$ 195,072
Research and development expense [Abstract]
Milestone payment as required by licensing agreement				$ 500,000
Numerator:
Net loss as reported	$ (12,224,000)	$ (13,346,000)	$ (33,486,000)	(30,500,000)
Less: income from change in fair value of warrant liability	0	0	(1,525,000)	0
Numerator for diluted net loss per common share	$ (12,224,000)	$ (13,346,000)	$ (35,011,000)	$ (30,500,000)
Denominator:
Basic weighted average common shares outstanding (in shares)	54,792	43,444	49,235	38,061
Dilutive common shares from assumed warrant exercises (in shares)	0	0	1,142	0
Diluted weighted average common shares outstanding (in shares)	54,792	43,444	50,377	38,061
Potential common stock issuable upon exercise of stock options and warrants (in shares)			10,700	12,000

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions				1 Months Ended		9 Months Ended
	Nov. 05, 2013	May 31, 2013	May 15, 2013	Nov. 30, 2013	Oct. 31, 2013	Sep. 30, 2013	Jun. 11, 2013
ATM Program [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock issued in public offering (in shares)					713,920
Period of agency agreement						3 years
Maximum value of potential common stock available for issue					$ 23.0	$ 25.0
Percentage sales commission on shares (in hundredths)						3.00%
Registered Public Offerings [Member]
Stockholders' Equity [Line Items]
Number of shares of common stock issued in public offering (in shares)	25,000,000		9,500,000
Per share price of common stock issuance (in dollars per share)	$ 2.00		$ 1.50
Gross proceeds from offering			$ 14.3
Net proceeds from issuance of common stock			$ 13.2
Over allotment exercise period	30 days		30 days
Number of additional shares of common stock that may be issued upon exercise of over allotment (in shares)	3,750,000		1,425,000
Number of shares of common stock issued upon exercise of over allotment (in shares)		1,347,000		3,750,000
Net proceeds from over allotment exercised				$ 7.1
Restriction period for issuing or selling securities						90 days
Registered Public Offerings [Member] \| Subsequent Event [Member]
Stockholders' Equity [Line Items]
Net proceeds from over allotment exercised		$ 1.9
June 2010 CEFF [Member]
Stockholders' Equity [Line Items]
Life of agreement to purchase shares						3 years
Number of shares expired under the agreement (in shares)							1,100,000

Long-term Debt (Details) shares in Thousands	3 Months Ended		9 Months Ended
Long-term Debt (Details) shares in Thousands	Sep. 30, 2013 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)
Long-term Debt [Abstract]
Date facility agreement entered			Feb. 13, 2013
Loan facility, maximum amount	$ 30,000,000		$ 30,000,000
First disbursement under loan facility	10,000,000		10,000,000
Second disbursement under loan facility	$ 20,000,000		$ 20,000,000
Loan facility payment terms			The principal amount of the loan is payable in equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Facility agreement, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) our “Net Sales” (defined below) for the immediately preceding 12-month period are at least $20 million, or (ii) our “Equity Value” (defined below) is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (x) our “Net Sales” for the immediately preceding 12 month period are at least $30 million, or (ii) our “Equity Value” is at least $250 million.
Transaction fee, percentage (in hundredths)			1.50%
Cash interest rate under loan facility (in hundredths)	8.75%		8.75%
Percentage sale of assets (in hundredths)			50.00%
Number of shares under issued warrants (in shares) \| shares	2,300		2,300
Exercise price of warrants (in dollars per share) \| $ / shares	2.81		2.81
Number of shares under unissued warrants (in shares) \| shares	4,660		4,660
Percentage of common stock to single holder, maximum (in hundredths)			9.985%
Fair value of warrants issued upon advance of initial disbursement	$ 3,800,000		$ 3,800,000
Transaction fee	150,000		$ 150,000
Significant unobservable input assumptions of Level 3 valuations [Abstract]
Historical Volatility			101.00%
Expected Term (in years)			6 years
Risk-free interest rate			1.175%
Carrying value of Facility Agreement [Abstract]
Note Payable	10,000,000		$ 10,000,000
Unamortized discount	(3,674,000)		(3,674,000)		$ 0
Long-term debt, net of discount	6,326,000		6,326,000
Interest expense [Abstract]
Cash interest expense	221,000	$ 0	551,000	$ 0
Non-cash amortization of debt discount	125,000	0	302,000	0
Amortization of debt costs	5,000	0	13,000	0
Total interest expense	$ 351,000	$ 0	$ 866,000	$ 0

Stock Options and Stock-based Employee Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Options and Stock-based Employee Compensation [Abstract]
Weighted-average vesting period of stock options			3 years
Weighted-average assumptions used in estimating fair value of stock options [Abstract]
Weighted average expected volatility (in hundredths)			110.00%	110.00%
Weighted average expected term (in years)			4 years 8 months 12 days	4 years 9 months 18 days
Weighted average risk-free interest rate (in hundredths)			0.74%	0.79%
Expected dividends (in hundredths)			0.00%	0.00%
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	$ 641	$ 474	$ 1,604	$ 1,277
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	210	150	551	388
Selling, General & Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	$ 431	$ 324	$ 1,053	$ 889

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2013
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 4 – Stockholders’ Equity Registered Public Offerings On May 15, 2013, we completed a registered public offering of 9.5 million shares of our common stock, at a price of $1.50 per share resulting in gross proceeds of $14.3 million ($13.2 million net). We also granted the underwriter a 30-day option to purchase up to an additional 1.425 million shares of common stock at an offering price of $1.50 per share. On May 31, 2013, the underwriter exercised its option and purchased 1.347 million additional shares of common stock for net proceeds to us (after underwriter fees) of $1.9 million. In connection with this offering, we agreed not to issue or sell (with certain limited exceptions) securities for a period of 90 days after the date of the prospectus supplement ending August 8, 2013. Regarding our ATM Program, we agreed not to issue or sell securities for a period of 30 days after the date of the underwriting agreement ending on June 9, 2013. At-the-Market Program In February 2013, we entered into an At-the-Market Equity Offering Sales Agreement with Stifel, under which Stifel, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $25 million of our common stock over a three-year period. We are not required to sell any shares at any time during the term of the ATM Program. We have agreed to pay Stifel a commission of 3% of gross proceeds of any sales of shares. See, Note 17, “Subsequent Events – ATM Program,” to the consolidated financial statements in our 2012 Form 10-K. Committed Equity Financing Facility (CEFF) We had a CEFF dated June 11, 2010 with Kingsbridge Capital Limited (Kingsbridge), under which, for a period of up to three years, Kingsbridge was committed to purchase, subject to certain conditions, newly issued shares of our common stock. Our ability to access the CEFF was subject to certain covenants and conditions, including stock price and volume limitations. For a detailed description of our CEFF, see, Note 10, “Stockholders’ Equity – Registered Public Offerings – Committed Equity Financing Facility (CEFF),” to the consolidated financial statements in our 2012 Form 10-K. The CEFF expired on June 11, 2013 with approximately 1.1 million available shares not issued.

Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Historical Volatility (in hundredths)	101.00%
Expected Term (in years)	6 years
Risk-free interest rate (in hundredths)	1.175%
Minimum [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Historical Volatility (in hundredths)	55.00%	56.00%
Expected Term (in years)	7 months 6 days	1 year 4 months 24 days
Risk-free interest rate (in hundredths)	0.05%	0.16%
Maximum [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Historical Volatility (in hundredths)	61.00%	80.00%
Expected Term (in years)	2 years 4 months 24 days	3 years 2 months 12 days
Risk-free interest rate (in hundredths)	0.45%	0.36%

Common Stock Warrant Liability (Details) $ in Thousands	Feb. 22, 2011 USD ($) $ / shares shares	Feb. 23, 2010 USD ($) $ / shares shares	May 13, 2009 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)
Five Year Warrant 1 [Member]
Class of Warrant or Right [Line Items]
Exercisable period of warrants			5 years
Estimated fair value of warrants accounted for as derivative liabilities [Abstract]
Issuance Date			May 13, 2009
Number of Warrant Shares Issuable (in shares) \| shares			466,667
Exercise Price (in dollars per share) \| $ / shares			17.25
Warrant Expiration Date			May 13, 2014
Fair Value of Warrants \| $			$ 3,360	$ 0
Five Year Warrant 2 [Member]
Class of Warrant or Right [Line Items]
Exercisable period of warrants		5 years
Estimated fair value of warrants accounted for as derivative liabilities [Abstract]
Issuance Date		Feb. 23, 2010
Number of Warrant Shares Issuable (in shares) \| shares		916,669
Exercise Price (in dollars per share) \| $ / shares		12.75
Warrant Expiration Date		Feb. 23, 2015
Fair Value of Warrants \| $		$ 5,701		2
Five Year Warrant 3 [Member]
Class of Warrant or Right [Line Items]
Exercisable period of warrants	5 years
Estimated fair value of warrants accounted for as derivative liabilities [Abstract]
Issuance Date	Feb. 22, 2011
Number of Warrant Shares Issuable (in shares) \| shares	4,948,750
Exercise Price (in dollars per share) \| $ / shares	1.50
Warrant Expiration Date	Feb. 22, 2016
Fair Value of Warrants \| $	$ 8,004			$ 4,676

Fair Value of Financial Instruments (Details) - Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Assets [Abstract]
Fair Value	$ 20,277	$ 23,777
Level 1 [Member]
Assets [Abstract]
Fair Value	20,277	23,777
Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Money Markets [Member]
Assets [Abstract]
Fair Value	19,877	23,377
Money Markets [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	19,877	23,377
Money Markets [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Money Markets [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Certificate of Deposit [Member]
Assets [Abstract]
Fair Value	400	400
Certificate of Deposit [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	400	400
Certificate of Deposit [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Certificate of Deposit [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Common Stock Warrant Liability [Member]
Liabilities [Abstract]
Fair Value	4,678	6,305
Common Stock Warrant Liability [Member] \| Level 1 [Member]
Liabilities [Abstract]
Fair Value	0	0
Common Stock Warrant Liability [Member] \| Level 2 [Member]
Liabilities [Abstract]
Fair Value	0	0
Common Stock Warrant Liability [Member] \| Level 3 [Member]
Liabilities [Abstract]
Fair Value	$ 4,678	$ 6,305

Fair Value of Financial Instruments, Level 3 Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Fair value measurements of common stock warrants using significant unobservable inputs (level 3)
Balance at beginning of period	$ 6,305
Balance at end of period	$ 4,678
Exercisable period of warrants	5 years
Level 3 [Member]
Fair value measurements of common stock warrants using significant unobservable inputs (level 3)
Balance at beginning of period	$ 6,305	$ 6,996
Exercise of warrants		(136)
Change in fair value of common stock warrant liability	(1,627)	5,063
Balance at end of period	$ 4,678	$ 11,923